N-(3-Chlorophenyl)-2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)acetamide

Catalog No. :
ACLRPQ994
CAS No. :
318235-37-9
Molecular Formula :
C16H14ClN3O2
Molecular Weight :
315.76

IUPAC Name:N-(3-chlorophenyl)-2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)acetamide

N-(3-Chlorophenyl)-2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$83.00Login to see priceInquiryInquiry
100mg95%$120.00Login to see priceInquiryInquiry
1g95%$408.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(3-Chlorophenyl)-2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)acetamide
IUPAC NameN-(3-chlorophenyl)-2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)acetamide
MDL No.MFCD01183986
Molecular FormulaC16H14ClN3O2
Molecular Weight315.76
SMILESO=C(NC1=CC=CC(Cl)=C1)CC2NC3=C(C=CC=C3)NC2=O
InChI KeyXJDUGUNLARAKDP-UHFFFAOYSA-N
SynonymN-(3-CHLORO-PHENYL)-2-(3-OXO-1,2,3,4-TETRAHYDRO-QUINOXALIN-2-YL)-ACETAMIDE;2-Quinoxalineacetamide, N-(3-chlorophenyl)-1,2,3,4-tetrahydro-3-oxo-;N-(3-CHLOROPHENYL)-2-(3-OXO-1,2,3,4-TETRAHYDRO-2-QUINOXALINYL)ACETAMIDE
CAS No.318235-37-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Synthetic Route by SureRoute

1. ACLRPQ994 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLRPQ994 route product structure diagram
    ACLRPQ994318235-37-9
Inquiry

2. ACLRPQ994 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLRPQ994 route product structure diagram
    ACLRPQ994318235-37-9
Inquiry

Comments (0)